Project ALS is pleased to share that the FDA has approved the drug edaravone – the first approved ALS treatment in over 20 years.
Edaravone, a free radical scavenger, appears to react with nerve-damaging compounds generated as part of the disease process. After six months of treatment, on top of standard-of-care, data showed the intravenous drug reduced the rate of functional decline in patients by about a third.
Read more
News
Neuroscience Publishes Special Issue Commemorating Project ALS Research Leader’s Legacy
The current issue of Neuroscience journal is dedicated to the staggering contributions to science made by longtime Project ALS Research Advisory Board Chair Thomas M. Jessell, PhD, before his death from the rare neurodegenerative disease progressive supranuclear palsy on April 28, 2019, at 67.
December 11, 2020
No Comments
